Mark Balk
About Mark Balk
Mark Balk is the Senior Director of HEOR at BeiGene in the United States, with extensive experience in Medical Science Liaisons and a background in pharmacy.
Current Role at BeiGene
Mark Balk is currently serving as the Senior Director for HEOR (Health Economics and Outcomes Research) at BeiGene in the United States. He began this role in July 2019. In this capacity, he is responsible for overseeing health economics and outcomes research initiatives, contributing to strategic planning, and ensuring that research outcomes align with organizational goals.
Previous Experience at Verastem Oncology
Prior to his current role, Mark Balk worked at Verastem Oncology as the Regional Director of Medical Science Liaisons (MSLs) from 2018 to 2019. During his one-year tenure, he led regional efforts in deploying MSLs, ensuring scientific support and fostering relationships with key stakeholders.
Tenure at Genentech
From 2016 to 2018, Mark Balk was employed at Genentech as the Associate Director for BioOncology - Medical Science Liaisons. Over his two-year period at Genentech, he managed teams of MSLs specialized in oncology, contributing to medical and scientific advancements in the field.
Roles at Medivation
Mark Balk held multiple positions at Medivation between 2012 and 2016. Initially, he served as a Senior Medical Science Liaison from 2012 to 2014. Subsequently, he was promoted to Regional Director of MSLs, a role he held from 2014 to 2016. His comprehensive work at Medivation included overseeing MSL activities and enhancing the effectiveness of medical communications.
Educational Background
Mark Balk has an extensive educational background in pharmacy and pharmacy administration. He obtained his PharmD from the University of Florida between 2003 and 2005. Prior to that, he earned both an MS in Pharmacy Administration (1990-1995) and a BS in Pharmacy (1980-1985) from the University of Utah. Additionally, he holds a BCPS certification, underscoring his expertise in pharmacotherapy.